AI Terminal
SEED INNOVATIONS LIMITED
Regulatory Filings • Sep 16, 2022
7909_rns_2022-09-16_38406af6-1a0e-46a9-b073-6b543c241e18.html
Regulatory Filings
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 7427Z
Seed Innovations Limited
16 September 2022
Seed Innovations Ltd / AIM: SEED / Sector: Closed End Investments
16 September 2022
SEED Innovations Ltd ("SEED" or, the "Company")
Eurox - Change of Name to Avextra
SEED Innovations Ltd, the AIM quoted company investing in fast-growing and industry-leading businesses with a focus on the medical cannabis, health and wellness space, is pleased to announce that its portfolio company, Eurox, has rebranded to Avextra ('Avextra').
With the new name, Germany-based cannabis extracts manufacturer Avextra wants to emphasise its clear focus on the highest quality cannabis extracts and its commitment to the development of evidence-based cannabis medicines. Avextra will be exhibiting at the Expopharm Pharmacists Congress in Munich from 14-17 September 2022.
Avextra provides SEED with direct access into Germany, the largest cannabis market in Europe today. The vertically integrated production capabilities of Avextra cover cultivation in its Portuguese facility, to manufacturing in Germany thanks to an exclusive, long-term manufacturing agreement in place with an EU GMP certified German pharmaceutical company.
ENDS
For further information on the Company please visit www.seedinnovations.co or contact:
| Ed McDermott / Lance de Jersey |
SEED Innovations Ltd | E: [email protected] |
| James Biddle / Roland Cornish |
Beaumont Cornish Limited, Nomad |
T: +44 (0) 207 628 3396 |
| Isabella Pierre / Damon Heath |
Shard Capital Partners LLP | T: +44 (0)20 7186 9927 |
| Catherine Leftley /Isabelle Morris/ Max Bennett |
St Brides Partners Ltd, Financial PR |
E: [email protected] |
Notes
SEED Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early-stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAGRGDCRUBDGDL